<DOC>
	<DOCNO>NCT02047903</DOCNO>
	<brief_summary>This observational study investigate efficacy , safety , tolerability symptom control GIOTRIF ( Afatinib ) daily routine first-line therapy patient locally advance metastatic NSCLC harbor EGFR-mutations . Eligible NSCLC patient , treat physician decide initiate treatment GIOTRIF first line accord local label , follow approximately 24 month .</brief_summary>
	<brief_title>GIOTRIF First Line Therapy Advanced NSCLC With EGFR-mutations</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : EGFR tyrosine kinase inhibitor ( TKI ) naive patient histologically confirm locally advanced metastatic NSCLC activate EGFRmutations Age &gt; = 18 year No diagnostic therapeutic measure beyond routine clinical practice require Patients treat physician decide initiate treatment GIOTRIF Written inform consent prior inclusion Exclusion criterion : Contraindication Afatinib accord Summary Product characteristic Participation another clinical study 30 day end treatment Prior systemic chemotherapy ( Neo/adjuvant therapy permit ) Previous treatment EGFRtyrosine kinase inhibitor Patients willing able fill quality life questionnaires Patients miss impaired legal capacity Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>